Page last updated: 2024-11-04

gatifloxacin and Macular Degeneration

gatifloxacin has been researched along with Macular Degeneration in 1 studies

Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.

Macular Degeneration: Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dorrepaal, SJ1
Gale, J1
El-Defrawy, S1
Sharma, S1

Other Studies

1 other study available for gatifloxacin and Macular Degeneration

ArticleYear
Resistance of ocular flora to gatifloxacin in patients undergoing intravitreal injections.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2014, Volume: 49, Issue:1

    Topics: Administration, Topical; Aged; Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclona

2014